What is the human clinical evidence regarding the efficacy and safety of CJC‑1295 (long‑acting growth‑hormone‑releasing hormone analog) and ipamorelin (selective growth‑hormone secretagogue)?

Human Clinical Evidence for CJC-1295 and Ipamorelin

Neither CJC-1295 nor ipamorelin has FDA approval for any indication, and there is no high-quality clinical evidence supporting their efficacy or safety for performance enhancement, anti-aging, or musculoskeletal recovery—these compounds should not be used outside of research settings.

Critical Evidence Gap

The FDA drug label evidence provided 1, 2 pertains to completely unrelated medications (ipratropium/albuterol inhalers and meclizine for motion sickness)—not CJC-1295 or ipamorelin. This reflects a fundamental problem: these peptides lack regulatory approval and have no official prescribing information.

CJC-1295: Limited Human Data

What We Know from Research

CJC-1295 is a long-acting GHRH analog designed to bind albumin, extending its half-life to 5.8-8.1 days 3. Two small studies from 2006 examined healthy adults:

• Single-dose study: CJC-1295 increased mean GH levels 2- to 10-fold for ≥6 days and IGF-I levels 1.5- to 3-fold for 9-11 days in healthy subjects (ages 21-61) 3
• Pulsatility study: A single injection in healthy men (ages 20-40) increased basal GH levels 7.5-fold and mean GH 46%, with IGF-I rising 45% while preserving pulsatile secretion 4
• Proteomic changes: Treatment altered serum protein profiles (apolipoprotein A1, transthyretin, albumin fragments), but clinical significance remains unknown 5

Critical Limitations

• No disease-state studies: All data come from healthy volunteers, not patients with growth hormone deficiency
• No long-term safety data: Maximum follow-up was 49 days 3
• No efficacy endpoints: Studies measured biochemical changes only—no functional outcomes, body composition improvements, or performance metrics
• Sample sizes: Extremely small (typically <20 subjects per study)
• Age of evidence: Primary data is nearly 20 years old with no subsequent rigorous trials

Ipamorelin: Virtually No Human Evidence

There are no published peer-reviewed clinical trials of ipamorelin in humans. The compound is mentioned only in review articles discussing growth hormone secretagogues as a class 6, 7, 8.

What Reviews Report

• Ipamorelin is classified as a selective ghrelin receptor agonist (growth hormone secretagogue) 6
• Theoretical mechanism: stimulates GH release without affecting cortisol or prolactin (based on preclinical data)
• Zero human pharmacokinetic, pharmacodynamic, safety, or efficacy data in peer-reviewed literature

Safety Concerns

Known Risks from GH Secretagogue Class

Based on limited data from other similar compounds 7:

• Metabolic: Decreased insulin sensitivity, elevated blood glucose, potential diabetes risk
• Endocrine: Prolactin and cortisol elevations (compound-dependent), appetite stimulation
• Fluid retention: Edema, joint pain, carpal tunnel syndrome
• Injection site reactions: Pain, erythema
• Unknown long-term risks: Cancer incidence, cardiovascular events, mortality effects unstudied

Specific Regulatory Warnings

The 2024 review 6 emphasizes that these "research compounds" operate in unregulated supply chains with:

• Uncertain product composition and purity
• Unknown actual doses despite labeling
• No quality control or pharmaceutical-grade manufacturing
• Contamination risks

Regulatory Status

Both compounds lack approval from any major regulatory agency (FDA, EMA, Health Canada) for any indication 6, 8. They are:

• Prohibited by the World Anti-Doping Agency (WADA) 9
• Marketed illegally as "research chemicals" direct-to-consumer
• Not subject to FDA oversight for safety, efficacy, or manufacturing standards

Approved Alternatives for Legitimate Indications

If a patient has confirmed adult growth hormone deficiency (not anti-aging or performance goals), evidence-based options include 10, 11:

• Daily recombinant human GH: FDA-approved since 1996 with extensive safety data
• Somapacitan: Once-weekly long-acting GH approved in 2020, with demonstrated efficacy in body composition, visceral fat reduction, and favorable safety profile in controlled trials 11

These require:

• Documented GHD via provocative testing (except in specific structural/genetic cases)
• Appropriate clinical indications per Endocrine Society guidelines 10
• Ongoing monitoring of IGF-I levels, glucose metabolism, and potential tumor recurrence

Clinical Recommendation

Do not prescribe or recommend CJC-1295 or ipamorelin. If patients report self-administration:

1. Document exposure: Specific compounds, doses, duration, source, stacking with other peptides
2. Screen for complications: Fasting glucose/HbA1c, IGF-I levels, prolactin, lipid panel, symptoms of fluid retention or joint pain
3. Counsel on risks: Unknown composition, lack of safety data, potential for serious endocrine/metabolic harm, legal/regulatory issues
4. Evaluate underlying goals: If legitimate concern for GHD exists, pursue proper diagnostic workup per guidelines 10
5. Recommend discontinuation: No evidence supports benefit; substantial uncertainty about harm

The absence of rigorous human trials, combined with unregulated manufacturing and unknown long-term safety, makes these compounds inappropriate for clinical use outside of properly conducted research protocols.